Lineage Cell Therapeutics (LCTX) Enterprise Value (2010 - 2026)

Lineage Cell Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$63.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 29.67% year-over-year to -$63.9 million; the trailing twelve-month figure through Mar 2026 stood at -$63.9 million (down 29.67% YoY), and the FY2025 full-year result was -$62.2 million, down 39.99% from the prior year.
• Enterprise Value for Q1 2026 stood at -$63.9 million, down from -$62.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$33.5 million in Q3 2025, with the low at -$81.3 million in Q1 2022.
• Historically, Enterprise Value has averaged -$51.0 million across 5 years, with a median of -$47.3 million in 2023.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 40.63% — and 2025, when it plunged 39.99%.
• Lineage Cell Therapeutics' Enterprise Value stood at -$59.3 million in 2022, then surged by 37.77% to -$36.9 million in 2023, then fell by 20.37% to -$44.4 million in 2024, then slumped by 39.99% to -$62.2 million in 2025, then slipped by 2.8% to -$63.9 million in 2026.
• The last three Enterprise Value figures came in at -$63.9 million (Q1 2026), -$62.2 million (Q4 2025), and -$33.5 million (Q3 2025), per Business Quant data.